Korean J Gastroenterol.
2010 Nov;56(5):324-328. 10.4166/kjg.2010.56.5.324.
A Case of Psoriasis Induced by Infliximab Treatment for Crohn's Disease
- Affiliations
-
- 1Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea. n-hkim@paik.ac.kr
- 2Department of Dermatology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
- KMID: 1718375
- DOI: http://doi.org/10.4166/kjg.2010.56.5.324
Abstract
- Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has adverse events including infusion reactions, opportunistic infections, and the potential for the event such as reactivation of latent tuberculosis. Cutaneous adverse reactions of TNF-alpha agents include skin rash, urticaria, pruritus, lupus-like eruption, and injection site reactions. Most of all, psoriasis or psoriasiform dermatitis induced by infliximab treatment for Crohn's disease is rarely reported in Korea. We report a case of psoriasis induced by infliximab treatment for Crohn's disease with a review of world literature.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis
- Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease
- Development of Renal Disorder in a Patient Receiving Infliximab (Remicade(R)) for Psoriasis
- A Case of Pustular Psoriasis Developed during Infliximab Treatment for Crohn's Disease
- Infliximab: Effective Therapy for Pustular Psoriasis
